The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
Open accessAbstract
Purpose: Thalidomide is effective in the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). However, the role of thalidomide in the post-autologous stem cell transplantation (ASCT) context remains unclear. This study assessed whether the addition of thalidomide consolidation following ASCT would improve the durability of responses achieved and overall survival. Patients and Methods: Between January 2002 and March 2005, 269 patients with newly diagnosed MM who achieved disease stabilization or better with conventional induction chemotherapy received a single high-dose melphalan conditioned ASCT. Post-ASCT, 129 patients were randomly assigned to receive indefinite prednisolone maintenance therapy (control group) and 114 to receive the same in addition to 12 months of thalidomide consolidation (thalidomide group). The primary study end points were progression-free survival (PFS) and overall survival (OS). The secondary end point was tolerability. Results: After a median follow-up of 3 years, the postrandomization 3-year PFS rates were 42% and 23% (P < .001; hazard ratio [HR], 0.5; 95% CI, 0.35 to 0.71) and the OS rates were 86% and 75% (P = .004; HR, 0.41; 95% CI, 0.22 to 0.76) in the thalidomide and control groups, respectively. There was no difference in survival between groups 12 months after disease progression (79% v 77%; P = .237). Neurological toxicities were more common in the thalidomide arm but there were no differences between arms for thromboembolic events. Conclusion: Consolidation therapy with 12 months of thalidomide combined with prednisolone prolongs survival when used after a single high-dose therapy supported ASCT in patients with newly diagnosed MM. Furthermore, thalidomide consolidation therapy did not adversely impact on survival in the subsequent salvage setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 127
RetractedModeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 667
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Guidelines on the diagnosis and management of multiple myeloma 2005
Smith, A., Wisloff, F., Samson, D., & the UK Myeloma Forum, N. M. S. G. A. B. C. F. S. I. H. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05867.x · Cited by 311
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., Briggs, A. D., Mills, G. M., Barlogie, B., & Salmon, S. E. (2002) · Blood · doi:10.1182/blood.v99.9.3163 · Cited by 240
Stewart, A. K., Chen, C. I., Howson‐Jan, K., White, D. J., Roy, J., Kovacs, M. J., Shustik, C., Sadura, A., Shepherd, L. E., Ding, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1106 · Cited by 67
Multiple myeloma: the death of VAD as initial therapy
Rajkumar, S. V. (2005) · Blood · doi:10.1182/blood-2005-04-1451 · Cited by 31
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M. V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 877
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Metadata
- Authors
- Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J., & Kennedy, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-04-10
- Volume
- 27
- Issue
- 11
- Pages
- 1788-1793
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135514413
- Cited by
- 332
- References
- 15
- FWCI
- 31.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.